Page 389 - Binder2

In modern specialty medicine, revenue doesn’t just come
from knowledge—it comes from what can be coded, billed,
and reimbursed. That means:

• Every infusion has a CPT code.
• Every injection has a modifier.
• Every pre-authorization, administration, and
monitoring step becomes part of a revenue cycle.

In this system, the act of giving the drug often pays more
than knowing which drug to give.

So what happens when the most effective, scalable,
immune-harmonizing therapies no longer require a
procedure?

What happens when biologics are shelf-stable, taken at
home, and don’t demand a nurse, chair, or crash cart?

This shift doesn’t just disrupt logistics.
It threatens the financial scaffolding of many clinical
practices.

The Procedure Economy

To understand the scope of the disruption, consider how
deeply procedures are embedded in specialty care
economics:

• Infusion centers operate as profit engines, billing
not just for the drug but for IV setup, space,
monitoring, and post-care documentation.
• Specialist practices often rely on biologic
administration to make up for unreimbursed

387